Related Experiment Video
Updated: Dec 31, 2025
Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes
Published on: June 28, 2024
Long-chain polyunsaturated fatty acids and the preterm infant: a case study in developmentally sensitive nutrient
1Division of Nutritional Sciences, Cornell University, Ithaca, NY jtb4@cornell.edu.
Insights
Long-chain polyunsaturated fatty acids (PUFAs) like docosahexaenoic acid and arachidonic acid are crucial in infant formulas. Preclinical studies significantly shaped human trials, highlighting the need to re-evaluate essential fatty acid concepts.
Area of Science:
- * Nutritional Science
- * Developmental Pediatrics
- * Biochemistry
Background:
- * Infant formulas commonly contain docosahexaenoic acid (DHA) and arachidonic acid (ARA), long-chain polyunsaturated fatty acids (PUFAs) approved in 2001.
- * Essentiality of n-6 PUFAs for skin integrity established in the 1950s, while n-3 PUFAs' significance recognized later.
- * Historical reliance on animal studies for nutrient mechanisms shifted towards complex human trials.
Purpose of the Study:
- * To analyze the influence of preclinical animal studies on human clinical trials of infant formula PUFAs.
- * To re-evaluate the essential fatty acid concept considering historical and current scientific evidence.
- * To identify barriers in understanding the essentiality of n-3 PUFAs in infant nutrition.
Main Methods:
- * Retrospective analysis of preclinical animal studies and human clinical trials.
- * Examination of historical research on essential fatty acids (EFAs).
- * Review of factors influencing the study of PUFAs, including nutrient sources and study designs.
Main Results:
- * Preclinical studies were pivotal in designing and interpreting human trials for DHA and ARA in infant formula.
- * Challenges in assessing n-3 PUFA functions (neural development) compared to n-6 PUFAs (skin integrity).
- * Inefficient use of C18 PUFAs from vegetable oils versus direct use of C20/C22 PUFAs.
Conclusions:
- * Re-evaluation of the essential fatty acid concept is needed based on the totality of evidence.
- * Advances in infant nutrition, especially for premature infants, require integrating all preclinical and clinical data.
- * Understanding PUFA essentiality necessitates considering both animal and human study outcomes.
Abstract:
The vast majority of infant formulas in the United States contain the long-chain polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (22:6n-3) and arachidonic acid (20:4n-6), which were first permitted by the US Food and Drug Administration in 2001. As a scientific case study, preclinical animal studies of these nutrients definitively influenced the design and interpretation of human clinical studies. Early studies were tied to the availability of test substances, and in hindsight suggest re-evaluation of the essential fatty acid concept in light of the totality of available evidence. Research in the 1950s established the essentiality of n-6 PUFAs for skin integrity; however, widespread recognition of the essentiality of n-3 PUFAs came decades later despite compelling evidence of their significance. Barriers to an understanding of the essentiality of n-3 PUFAs were as follows: 1) their role is in neural function, which is measured only with difficulty compared with skin lesions and growth faltering that are apparent for n-6 PUFAs; 2) the experimental use of vegetable oils as PUFA sources that contain the inefficiently used C18 PUFAs rather than the operative C20 and C22 PUFAs; 3) the shift from reliance on high-quality animal studies to define mechanisms that established the required nutrients in the first part of the 20th century to inherently challenging human studies. Advances in nutrition of premature infants require the best practices and opinions available, taking into account the totality of preclinical and clinical evidence.
More Related Videos
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:18Lipids: Dietary Sources and Requirements
03:38Structure of Lipids
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
01:27Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...